Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020961 | 0.94 | TK1 (0.47) | TK1MAPK1TK2CYP1A2GAA | |
| SCHEMBL26793575 | 0.94 | MAPK1 (0.41) | TK1MAPK1HPGDTK2 | |
| SCHEMBL25799801 | 0.93 | TK1 (0.48) | TK1MAPK1HPGDTK2CYP1A2 | |
| SCHEMBL22946803 | 0.93 | TK1 (0.47) | TK1MAPK1HPGDTK2CYP1A2 | |
| SCHEMBL22946795 | 0.91 | TK1 (0.49) | TK1MAPK1HPGDTK2CYP1A2 | |
| SCHEMBL22198654 | 0.88 | TK1 (0.39) | TK1MAPK1HPGDTK2 | |
| SCHEMBL21090689 | 0.88 | TK1 (0.39) | TK1MAPK1HPGDTK2 | |
| SCHEMBL22380811 | 0.86 | TK1 (0.47) | TK1MAPK1TK2CYP1A2GAA | |
| SCHEMBL22020875 | 0.81 | MAPK1 (0.41) | TK1MAPK1HPGDTK2 | |
| SCHEMBL22260407 | 0.81 | MAPK1 (0.42) | TK1MAPK1HPGDTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | TK1 394/4885MAPK1 4645/4885HPGD 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.